Skip to main content
3D Medicines Inc. logo

3D Medicines Inc. — Investor Relations & Filings

Ticker · 1244 ISIN · KYG8872R1011 HKEX Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2023-07-20 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1244

About 3D Medicines Inc.

https://www.3d-medicines.com

3D Medicines Inc. is an oncology-focused, commercial-stage biopharmaceutical company specializing in the development and commercialization of next-generation immuno-oncology therapies. The company leverages global research and development capabilities and internal discovery platforms to advance a pipeline of innovative drug candidates. Its core mission is to address unmet medical needs in cancer treatment, aiming to transform cancer into a chronic disease and provide substantial value to patients and healthcare providers globally.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the company regarding unusual price and trading volume movements of its shares on specific dates. It explicitly states that the Board has made inquiries and confirms no inside information or material adverse changes exist. The document is an announcement to inform shareholders and the public about market activity and the company's status, not a financial report, management discussion, or regulatory filing of financial results. It is short (2265 characters) and serves as a market disclosure to comply with stock exchange rules about unusual trading activity. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into other specific categories like earnings release or management report.
2023-07-20 English
PLACING OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the placing of new shares under a general mandate by 3D Medicines Inc. It details the terms of the placing agreement, the number of shares to be placed, the placing price, conditions precedent, lock-up undertakings, and the intended use of proceeds. The content focuses on fundraising activities and capital structure changes, including share issuance and placement details. There is no indication that this is a full financial report, earnings release, or regulatory certification. The document is not a proxy statement, AGM material, or management discussion. It is a detailed capital/financing update about a share placing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2023-07-14 English
POSITIVE PROFIT ALERT
Earnings Release Classification · 95% confidence The document is titled 'POSITIVE PROFIT ALERT' and is an announcement made pursuant to the Listing Rules of the Hong Kong Stock Exchange and the Securities and Futures Ordinance. It provides preliminary unaudited management account figures for the six months ended June 30, 2023, including revenue and gross profit estimates. The document explicitly states that the interim results are still being finalized and that the figures are unaudited and preliminary. It also advises shareholders to wait for the official interim results announcement expected by the end of August 2023. The document is an earnings update or profit alert rather than a full interim report containing comprehensive financial statements or detailed analysis. It is not a full Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, and it is not a full Earnings Release (ER) in the sense of a formal quarterly earnings announcement but rather a profit alert. Given the nature of the document as a profit alert providing preliminary financial performance information, the most appropriate classification is Earnings Release (ER). The document length (5638 characters) supports that it is more than a brief note but still focused on key financial highlights rather than a full report. H1 2023
2023-07-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities, specifically share capital and issued shares for the month ended 30 June 2023. It details authorized share capital, issued shares, share options, and confirmations related to securities issuance. The document is regulatory in nature, providing updates on share capital and share movements rather than a full financial report or earnings release. It does not contain financial statements or management discussion but serves as a regulatory compliance filing about share capital movements. This fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like capital changes (SHA) or director dealings (DIRS). The document length and content confirm it is not merely an announcement of a report but a substantive regulatory filing.
2023-07-04 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on June 26, 2023. It details the voting outcomes on various resolutions including adoption of financial statements, re-election of directors, appointment of auditors, and approval of share option schemes. The document explicitly states it is announcing the results of the AGM and references the AGM Notice and AGM Circular. It does not contain the full AGM materials or presentations, nor is it the full annual report or financial statements themselves. The document is longer than 5,000 characters but is clearly an announcement of voting results rather than the report or presentation itself. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-06-26 English
Restricted Share Unit Scheme
Share Issue/Capital Change Classification · 95% confidence The document is titled '3D MEDICINES INC. SHARE INCENTIVE SCHEME' and contains detailed sections on definitions, administration, awards, vesting, share capital, and other terms related to a share incentive plan. It includes references to RSUs (Restricted Stock Units), the Board, the Department administering the scheme, and the Stock Exchange. The content is focused on the rules and terms of a share incentive scheme rather than financial results, management changes, or regulatory announcements. This type of document is typically related to share-based compensation plans and their governance. According to the filing definitions, this document fits best under 'Share Issue/Capital Change (SHA)' because it deals with share awards, share capital, and related capital structure matters. It is not an announcement or a brief summary but a detailed scheme document, so it is not a report publication announcement or regulatory filing. Therefore, the classification is SHA with high confidence.
2023-06-23 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.